VTVT · XBRL financial data

vTv Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VTVT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	6,414	4,005	2,018	0	1,017	0
Research and development	11,015	13,324	12,357	13,595	11,546	17,861
General and administrative	7,251	12,343	12,201	11,907	13,651	14,947
Total operating expenses	18,266	25,667	24,558	25,502	25,197	32,808
Operating income (loss)	(11,852)	(21,662)	(22,540)	(25,502)	(24,180)	(32,808)
Interest income	12	1	352	472	1,565	1,870
Interest expense	692	12	15	13	0	—
Other income (expense)	0	2,448	(3,616)	(1,497)	—	—
Income tax expense (benefit)	0	115	200	0	100	0
Net income (loss)	(8,499)	(12,987)	(19,164)	(20,250)	(18,462)	(26,974)

Fiscal years (VTVT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	5,747	13,415	12,126	9,446	36,746	88,932
Accounts receivable	158	57	173	102	62	—
Prepaid and other current assets	939	2,049	2,537	1,044	1,220	961
Total current assets	7,215	15,621	27,094	10,657	38,113	89,893
Property and equipment, net	367	278	207	117	28	—
Right-of-use asset	482	402	349	244	125	—
Total assets	14,789	25,474	33,238	11,018	38,266	89,899
Accounts payable	1,925	1,876	2,461	4,075	939	1,132
Total current liabilities	6,390	8,498	7,708	10,619	5,196	6,641
Lease liability, non-current	676	492	338	169	0	—
Total liabilities	10,996	10,252	27,399	29,567	23,965	25,462
Accumulated deficit	(290,036)	(248,834)	(265,524)	(281,042)	(299,718)	(326,692)
Total stockholders' equity	(80,102)	(9,740)	(10,740)	(24,680)	12,199	64,437
Total liabilities and equity	14,789	25,474	33,238	11,018	38,266	89,899

Fiscal years (VTVT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(8,499)	(12,987)	(19,164)	(20,250)	(18,462)	(26,974)
Stock-based compensation	1,009	2,356	1,272	1,578	2,757	3,775
Net cash from operating activities	(18,000)	(19,308)	(16,022)	(19,081)	(25,307)	(25,255)
Purchases of property and equipment	0	0	21	0	0	—
Net cash from investing activities	0	0	(21)	4,404	0	0
Proceeds from issuing common stock	14,426	26,757	0	0	2,463	0
Net cash from financing activities	19,470	26,976	14,754	11,997	52,607	77,441
Net change in cash	1,470	7,668	(1,289)	(2,680)	27,300	52,186

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
vTv Therapeutics	86,643	0	(11,443)*	not reported	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Ovid Therapeutics	11,327	733	(17,594)*	195.3M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Marimed	8,437	41,925	2,219*	403.0M	—	Q2 FY26 10-QJun 30, 2026
Aptose Biosciences	1,020	not reported	(5,841)	2.6M	0.2 quarters	Q1 FY26 10-QMar 31, 2026
Dare Bioscience	12,618	188	(6,775)*	15.3M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Lunai Bioworks	1,714	31*	(1,841)*	5.0M	0.9 quarters	Q4 FY26 10-KJun 30, 2026
Imunon	6,864	not reported	(3,025)*	5.6M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Lisata Therapeutics	10,443	0	(2,649)*	9.0M	3.9 quarters	Q2 FY26 10-QJun 30, 2026
Nanoviricides	2,794	not reported	(2,122)*	25.5M	1.3 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.